Articles from Dragonfleye Therapeutics Corp

Dragonfleye Therapeutics Corp. Takes Flight, Raising US$37.5 Million in Private Placement Offerings to Advance Novel Ocular Platform-Based Treatments

TORONTO, ON / ACCESS Newswire / October 26, 2026 / Dragonfleye Therapeutics Corp. ("Dragonfleye" or the "Company"), a patient-centered, innovation-focused company developing minimally invasive treatments for pathologic conditions in ophthalmology using its platform technology, today announced that it completed two non-brokered private placements of common shares during 2026, raising aggregate gross proceeds of US$37.5 million (the "Offerings"). Participants included healthcare-dedicated investors and existing shareholders.

By Dragonfleye Therapeutics Corp · Via ACCESS Newswire · October 26, 2026